This may reflect inherent heterogeneity in the signal transduction networks of the individual IBC cells, limited specificity of the CMAP profiles that are generated using a broad collection of cancer cell lines and thus are not reflective of breast cancer specific transcriptional responses, or the failure to identify robust and highly specific IBC co-expression modules due to the limited size and relative homogeneity (i.e., all ER-negative and basal-like samples) of the series of IBC preclinical models. The gene discussed is ESR1; the disease is cancer.